Keros Therapeutics earnings were -$168.1M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest KROS earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$45.3M, up 5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, KROS reported annual earnings of -$153.0M, with 46.2% growth. The next KROS earnings date is Nov 4, 2024.
What were Keros Therapeutics's earnings last quarter?
On KROS's earnings call on Invalid Date, Keros Therapeutics (NASDAQ: KROS) reported Q2 2024 earnings per share (EPS) of -$1.25, up 1.57% year over year. Total KROS earnings for the quarter were -$45.26 million. In the same quarter last year, Keros Therapeutics's earnings per share (EPS) was -$1.27.
The next KROS earnings call is Invalid Date. Add KROS to your watchlist to be reminded of Keros Therapeutics's next earnings date.
Is Keros Therapeutics profitable or losing money?
As of the last Keros Therapeutics earnings report, Keros Therapeutics is currently losing money. Keros Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$168.05 million, a 32.81% increase year over year.
What was KROS's earnings growth in the past year?
As of Keros Therapeutics's earnings date in Invalid Date, Keros Therapeutics's earnings has grown year over year. KROS earnings in the past year totalled -$168.05 million.
What are Keros Therapeutics's earnings expectations?
The current EPS estimate for Keros Therapeutics's earnings report in Invalid Date is -$1.28.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.